Clinical Trial: A Single-center Study of CM313 in Patients With Pemphigus

U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904040) titled 'A Single-center Study of CM313 in Patients With Pemphigus' on March 25.

Brief Summary: A prospective, single-center, single-arm clinical study aimed to explore the efficacy and safety of the anti-CD38 monoclonal antibody CM313 combined with low-dose glucocorticoids in patients with pemphigus.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Pemphigus

Intervention: BIOLOGICAL: CM313 injection

600 mg (4 mL per vial), administer once at Week 0, 1, and 2, and then every 6 months thereafter or determined based on clinical assessment

BIOLOGICAL: glucocorticoids

Administer medium- or long-acting glucocorticoids 1-3...